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Edited by Laszlo NagyAbstract Cytokines may provide signals for regulating human
monocyte matrix metalloproteinase-9 (MMP-9) activity. In this
study, we investigated the roles of interferons (IFN) type I/II and
transforming growth factor-b1 (TGF-b1) in MMP-9-mediated
invasiveness. MMP-9 antibody and inhibitor, IFNs and TGF-
b1 inhibited monocyte transmigration through Matrigel. IFNs
and TGF-b1 downregulated MMP-9 mRNA, protein and activ-
ity levels. The inhibitory action of IFNs was associated with the
STAT1/IRF-1 pathway since the JAK inhibitor AG490 blocked
STAT1 phosphorylation, IRF-1 synthesis and counteracted the
blockade of MMP-9 release. TGF-b1-mediated MMP-9 inhibi-
tion appeared STAT1/IRF-1-independent but reversed by the
protein tyrosine kinase inhibitor tyrphostin 25. Our data point
out the importance of IFNs and TGF-b1 in the control of mono-
cyte MMP-9-mediated extravasation.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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signaling1. Introduction
Monocytes inﬁltrating injured tissues (inﬂammation, wound
healing, tumors) play a crucial role by releasing cytokines, che-
mokines and matrix metalloproteinases (MMPs) which regu-
late cancer and inﬂammation [1–3]. Through their hydrolytic
abilities, MMPs are involved in a variety of biological pro-
cesses, such as proliferation, migration and invasion of cells,
tumor metastasis and angiogenesis [3]. Several investigations
suggest that MMP-9 (gelatinase B) production by monocytes
is associated with their diﬀerentiation into macrophages
[4–7]. MMP-9 is synthesized as a preproenzyme, secreted as
a proform (proMMP-9, 92 kDa) and its activation requires
proteolytic removal of a fragment of the N-terminal domain
[3]. MMP-9 is capable of degrading extracellular matrix
substrates (type I, IV, V, VII, XI collagens, ﬁbrin and laminin)Abbreviations: IFN, Interferon; MMP, matrix metalloproteinase;
TGF, transforming growth factor; TNF, tumor necrosis factor
*Corresponding author. Fax: +33 1 45 66 51 33.
E-mail addresses: nguyenj@necker.fr (J. Nguyen),
bauvois@necker.fr (B. Bauvois).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2005.09.012and non-matrix substrates [3,8,9]. Recent data demonstrated
that proMMP-9 binding to collagen type IV results in an enzy-
matic activation of proMMP-9 without loss of its NH2-termi-
nal propeptide [10].
Based on the evidence that MMP-9 is of critical importance
in cell invasion, current trials focus on the identiﬁcation of bio-
markers that could inhibit MMP-9 [11]. The promoter of
MMP-9 possesses several functional enhancer element binding
sites including three AP-1 sites, a non consensus NF-jB site,
an Ets site, an SP-1 site and a retinoblastoma element
[12,13]. Tumor necrosis factor-a (TNF-a) stimulates MMP-9
gene transcription in monocytes through activation of NF-
jB [14,15]. On the basis of their physicochemical and biologi-
cal properties, the interferon (IFN) family is subdivided into
type I IFNs (a,b) and type II (c). Cellular eﬀects of IFNs in-
clude inhibition of cell proliferation, and eﬀects on apoptosis,
immunomodulation, angiogenesis and leukocyte traﬃcking
[16–18]. IFN-c inhibits MMP-9 release in human monocytes
treated with exogenous TNF-a [19,20]. Transforming growth
factor-b1 (TGF-b1) is a multifunctional cytokine which inhib-
its cell proliferation, induces cell migration and angiogenesis
[21]. Discrepant data have been reported with regard to trans-
forming growth factor (TGF)-b1 action on monocyte MMP-9
expression. TGF-b1 could upregulate MMP-9 release in hu-
man TNF-a-treated monocytes and THP-1 cells [22,23] or
downregulate MMP-9 in monocytes [24].
IFN-c and TGF-b1 induce maturation of monocytes and
their precursors into macrophages [25–27]. Although without
any eﬀect on monocyte maturation, IFNs type I (a and b)
may activate signaling pathways common to IFN-c [28]. The
objective of the present study was to investigate the eﬀects of
TGF-b1 and IFNs on MMP-9 expression and transmigratory
properties of human monocytes. In this study, we demon-
strated that inhibition of MMP-9 in human monocytes by
IFN or TGF-b1 accounts for their reduced invasiveness. We
further explored the mechanisms by which IFNs and TGF-
b1 downregulate MMP-9 in monocytes, and we found that
these cytokines inhibited MMP-9 expression through separate
signaling pathways.2. Materials and methods
2.1. Reagents
Recombinant human (rh) TGF-b1, rh IFN-c (2 · 107 U/mg) and
rh proMMP-9 were supplied by R&D (Abindgton, UK). Rh IFN-
a2a (2 · 108 U/mg) and rh IFN-b (2 · 108 U/mg) were provided byation of European Biochemical Societies.
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(Geneva, Switzerland), respectively. Amino-phenyl mercuric acid
(APMA), bisindolylmaleimide, H-89, indomethacin, wortmannin,
and tyrphostin 25 were obtained from Sigma Chemicals Co.
(Saint-Louis, MO). AG490 (tyrphostin B42), PP2 and MMP-9
inhibitor ((2R)-[4-biphenylsulfonylamino]-N-hydroxy-3-phenylpropi-
onamide) were from Calbiochem (Darmsdat, Germany). SB203580
was from BioMol (Plymouth Meeting, PA).2.2. Antibodies
Irrelevant mouse (m)IgGs and monoclonal antibodies (mAbs)
(FITC or PE) speciﬁc for CD11b (mIgG1, BEAR 1) and CD14
(mIgG1, 134620) were obtained from Coulter/Beckman (Luminy,
France). Abs speciﬁc for phosphorylated-Y701 STAT1 (goat poly-
clonal IgG, Tyr 701), STAT1 (rabbit polyclonal IgG, E-23) and
IRF-1 (rabbit polyclonal IgG, C-20) were from Santa Cruz Biotechnol-
ogy (Tebu, France). Neutralizing anti-MMP-9 (mIgG1, AZC02) was
from R&D (Abingdon, UK). Anti-actin (mIgG1, C4) was from ICN
Biomedicals (Ohio, USA).2.3. Obtention of isolated monocytes and culture conditions
Human peripheral blood monocytes were isolated by Ficoll–
Hypaque density gradient (1.077 g/mL) centrifugation and further
adherence to plastic as described [26]. As assessed by ﬂow cytometry
analysis of the CD14 antigen, adherent cells contained P 95% mono-
cytes. Cells (0.5–1 · 106/mL) were cultured in RPMI 1640 medium/
10% FCS at 37 C, in the absence or presence of 1000 U/mL IFN-
a/-b/-c or 10 ng/mL TGF-b1 or various pharmacological inhibitors.
In some experiments, cells were pretreated with the antagonist
GW9662 or AG490 for 30 min before adding stimuli. After various
periods of incubation, cells were collected, washed twice, counted
with a Coulter Counter channelizer 256 (Coulter/Beckman). Diﬀeren-
tiation of cells into macrophages was determined according to the
change in morphology (by staining of cytocentrifuged cells with the
Hemacolor kit from Merck and light microscope examination). Cell
viability was assessed by trypan blue exclusion and the Coulter
Counter.
2.4. Flow cytometry analysis
Intact cells were immunostained as described [26]. Analysis was per-
formed in a FACS ﬂow cytometer analyzer (Becton-Dickinson, Moun-
tain View, CA).Values are given as percentages of positive cells.
2.5. ELISA
The culture supernatants from treated cells were tested for MMP-9
and TNF-a contents using commercial ELISA kits (R&D, Abingdon,
UK). Controls included FCS-supplemented RPMI 1640 medium incu-
bated under the same conditions. Detection level for TNF-a and
MMP-9 was 10 pg/mL.
2.6. RNA isolation, cDNA synthesis and PCR
RNA extraction from treated cells and cDNA synthesis were con-
ducted as described [29]. The cDNAs for human b2-microglobulin
(165 bp) and MMP-9 (296 bp) were ampliﬁed by PCR and primers
were designed according to published sequences [29]. MMP-9 cDNA
(296 bp) was ampliﬁed using the sense primer 5 0-GGA GAC CTG
AGA ACC AAT CTC-3 0 and the antisense primer 5 0-TCC AAT
AGG TGA TGT TGT CGT-3 0. b2-microglobulin cDNA (165 bp)
was ampliﬁed using the sense primer 5 0-CAT CCA GCG TAC TCC
AAA GA-3 0 and antisense 5 0-GAC AAG TCT GAA TGC TCC
AC-3 0. The PCR products were visualized by electrophoresis in 2%
agarose gel containing 0.2 lg/mL ethidium bromide. The NIH Image
1.63 software was used for the analysis.
2.7. Zymography
Analysis of MMP-9 activity was carried out in 7.5% (w/v)
SDS–PAGE containing 0.1% gelatin (w/v) as described elsewhere
[29]. Recombinant proMMP-9 (1 ng) and culture supernatants were
preincubated for 60 min at room temperature with 0.5 mM APMA
which activates the proform (92 kDa) to the activated form
(82 kDa). The NIH Image 1.63 software was used for the analysis of
the bands after acquisition in an Appligen densitometer (Oncor).2.8. Western blot analysis
Following stimulation of monocytes with IFN (1000 U/mL) or
TGF-b1 (10 ng/mL) for 18 h, total cell extracts were prepared as de-
scribed [30], separated on 12% polyacrylamide–SDS gels, transferred
to nitrocellulose and blotted as described [30]. Membranes were
hybridized with Abs for phosphorylated-STAT1 (pY-STAT1),
STAT1, IRF-1 and actin as described [30] using chemiluminescence
technique developed by Santa Cruz. Immunoreactive protein bands
were detected by autoradiography on Hyperﬁlms (Kodak). The NIH
Image 1.63 software was used for the quantitation of the bands.
2.9. In vitro invasion assay
Invasion was measured by assessement of monocyte migration rate
through an artiﬁcial membrane in Transwell cell cultures chambers
(Corning Costar, 8 lm pore size). Brieﬂy, membranes were precoated
with 25 lg of Matrigel (BD Biosciences, MA) on the upper surface.
Freshly isolated monocytes (1 · 105 cells in 100 ll RPMI) were seeded
into the upper well of the chamber, while the lower well was ﬁlled up to
the top (600 ll) with RPMI + 10% FCS as a chemoattractant. The
neutralizing MMP-9 antibody, its control isotype mIgG1, MMP-9
inhibitor, IFN-a/b/-c or TGF-b1 were added to the cells. After 18 h
at 37 C in 5% CO2, cells that had migrated through the matrigel-
coated ﬁlters were recovered from the lower compartment and counted
using the Cell Coulter Counter. Results from duplicates wells were ex-
pressed as means ± S.D.
2.10. Statistical analysis
Values are represented as means ± S.D. of n separate experiments.
The statistical signiﬁcance of diﬀerences was evaluated by ANOVA
using the StatView Student v1.0 software.3. Results
3.1. Synthesis and release of MMP-9 by cultured monocytes
Total RNA from cultured monocytes was isolated, reverse-
transcribed and subjected to PCR ampliﬁcation. Samples were
standardized for total cDNA content by assessing the presence
of identical amounts of b2-microglobulin transcripts. As
shown in Fig. 1A, MMP-9 PCR products were not detected
in freshly isolated monocytes (lane 1). Induced levels of
MMP-9 transcripts were already evident in monocytes cul-
tured for one day (Fig. 1A, lane 2) and persisted at day 7
(Fig. 1A, lane 4).
Using ELISAs, kinetic studies indicated a rapid and con-
comitant release in TNF-a and MMP-9 proteins in superna-
tants of cultured monocytes (Fig. 1B). MMP-9 production
by 24-h cultured monocytes was abolished in presence of neu-
tralizing TNF-a Ab but not with its isotype used as control.
Fig. 1B ascertaining the pivotal role of endogenous TNF-a
in monocyte MMP-9 induction. Zymography analysis of the
conditioned media from cultured monocytes showed the pres-
ence of a gelatinase activity at 92-kDa consistent with the pat-
tern of proMMP-9 (Fig. 1C, compare lanes 2 and 4) and
APMA treatment resulted in conversion of proMMP-9 to
the active form of 82-kDa size (Fig. 1C, lanes 3 and 5). Thus,
the upregulation of MMP-9 mRNA levels in cultured mono-
cytes is consistent with the induced levels of MMP-9 protein
and activity.
3.2. IFNs and TGF-b1 inhibit monocyte MMP-9 synthesis and
release
As described [25,26], IFN-c and TGF-b1 accelerate the
spontaneous diﬀerentiation of monocytes into macrophages
whereas IFNs type I (a and b) did not aﬀect monocyte matu-
ration (data not shown). Day 2-PCR reactions indicated that
Fig. 3. Eﬀects of IFNs and TGF-b1 on monocyte TNF-a release.
Monocytes (1 · 106) were cultured for two days in the absence or
presence of IFNs (1000 U/mL) or TGF-b1 (10 ng/mL) and culture
supernatants were assessed for TNF-a production measured by
ELISA. Data represent the mean of 4–13 independent experiments.
Values are expressed as means ± S.D.
Fig. 1. MMP-9 synthesis and release by in vitro cultured monocytes.
Freshly isolated monocytes (1 · 106) were cultured for 7 days. (A) PCR
analyses were performed as described in Section 2 using 2% agarose
gels. (B) Time course of MMP-9 and TNF-a production in the culture
supernatants of monocytes determined by ELISA. Data are expressed
as means ± S.D. (n = 4). (C) Analysis of gelatinolytic activity in the
culture media of day 2-monocytes. (C) Control culture medium
without cells; activation of monocyte proMMP-9 (lane 2) and rh
proMMP-9 (lane 4) by APMA (0.5 mM) results in the 82-kDa active
forms (lanes 3 and 5).
Fig. 2. Eﬀects of IFNs and TGF-b1 on monocyte MMP-9 expression.
Monocytes (1 · 106) were cultured for two days in the absence or
presence of IFNs (1000 U/mL) or TGF-b1 (10 ng/mL). (A) PCR
analyses of the eﬀects of IFNs and TGF-b1 on MMP-9 and b2-
microglobulin transcripts. (B) MMP-9 production measured by
ELISA. Data represent the mean of ﬁve independent experiments.
Values are expressed as means ± S.D. \P < 0.005 for IFN-a and IFN-c
compared with control; \\P < 0.080 for IFN-b compared with control;
\\\P < 0.0004 for TGF-b1 compared with control. (C) Analysis of
proMMP-9 and proMMP-2 gelatinolytic activities in the culture media
of untreated and treated monocytes.
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types of IFNs and TGF-b1 (Fig. 2A lanes 2–5). Furthermore,
we analyzed the ability of monocytes, before and after treat-
ment, to release proMMP-9 into the culture medium. ELISA
data showed that IFN-a/-b as well as the two diﬀerentiating
cytokines TGF-b1 and IFN-c blocked the production of
MMP-9 protein (Fig. 2B) and this was associated with reduced
gelatinolytic activity of MMP-9 (Fig. 2C). The correlation ob-
served between the levels of MMP-9 transcript and protein at
day 2 showed that TGF-b1 was much less eﬀective on MMP-9
expression compared with IFNs. Monocytes produced a 72-
kDa gelatinolytic activity representing proMMP-2 at very
low level compared with MMP-9, which was unaﬀected by
IFN or TGF-b1 treatment (Fig. 2C). IFN- and TGF-b1-med-
iated inhibition of MMP-9 release was time- and dose-depen-
dent with maximal IFN and TGF-b1 eﬀects being obtained
at 1000 U/mL and 10 ng/mL, respectively (data not shown).
These experiments indicate that IFNs and TGF-b1 inhibited
MMP-9 protein level which is likely the result of downregu-
lated MMP-9 mRNA levels.
3.3. Comparative eﬀects of IFNs and TGF-b1 on TNF-a release
Whether IFNs or TGF-b1 inhibited endogenous TNF-a re-
lease was investigated. A previous study already reported the
stimulatory eﬀect of IFN-c on TNF-a release by human
monocytes whereas IFN-a inhibited such production [31]. Asseen in Fig. 3, day 2-monocytes released detectable levels of
TNF-a (around 20 pg/mL/106 cells). TGF-b1 as well as IFN-
a/-b did not inﬂuence TNF-a production. Consistent with
[31], IFN-c enhanced TNF-a release (upto 160 pg/mL/106
cells) (Fig. 3). These data thus indicate that MMP-9 inhibition
was not related to a diminished production of endogenous
TNF-a, amd that IFN-c at 1000 U/mL was still capable of
reversing the activating eﬀect of 160 ng/mL TNF-a toward
MMP-9.
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signaling
We previously showed that IFNs type I and II inhibited
MMP-9 expression in a model of tumor epithelial cell line by
activating the STAT1/IRF1 signaling [30]. Since TGF-b1
could interfere with IFN signaling [32], we assessed whether
it could inhibit MMP-9 through the STAT/IRF-1 pathway.
IFNs activate STAT1 through tyrosine phosphorylation,
dimerization, nuclear translocation and DNA binding [28].
Activated STAT1 induces IRF-1 transcription [33]. Here,
IFN treatment induced tyrosine phosphorylation of STAT1
in whole cell lysates from monocytes (Fig. 4A, left panel). As
described [34], STAT1 levels were upregulated following IFN
stimulation (Fig. 4A, left panel). IFN stimulation led to an in-
crease in the levels of IRF-1 in whole cell lysates (Fig. 4A, left
panel). In contrast, TGF-b1 neither induced STAT1 tyrosine
phosphorylation nor enhanced IRF-1 protein (Fig. 4A, left pa-
nel). These data therefore indicated that IRF-1, downstream
mediator of STAT1, was eﬃciently induced by IFNs but not
by TGF-b1.
AG490 inhibits IFN-mediated JAK activity involved in
STAT1 tyrosine phosphorylation [35]. Since AG490
concentrations in culture medium >5 lM resulted in cell
toxicity, monocytes were therefore preincubated for 30 min
with 5 lM AG490 and subsequently treated with IFNs or
TGF-b1.Western analysis indicated that AG490 downregu-
lated tyrosine phosphorylated STAT1 and IRF-1 protein
levels in IFN-treated monocytes (Fig. 4A, right panel). In
contrast, the basal levels of IRF-1 in unstimulated and
TGF-b1-stimulated cells remained almost unchanged
(Fig. 4A, right panel). In parallel, AG490 diminished the
IFN-mediated inhibition of MMP-9 release by monocytes,
but was without eﬀect on TGF-b1-mediated MMP-9
inhibition (Fig. 4B). Together, these data indicate that
IFN-mediated MMP-9 inhibition in monocytes, but not
TGF-b1-mediated MMP-9 inhibition, was associated with
the STAT1/IRF-1 pathway.Fig. 4. Western blot analysis of STAT1, pY-STAT1 and IRF-1 proteins in mon
cultured in the absence or presence of IFNs (1000 U/mL) or TGF-b1 (10 ng/m
cytokine stimulation for 24 h. (A) Western blot analyses were performed as d
PAGE. (B) MMP-9 production in conditioned media of day-1 monocytes w
stimulation or AG490 stimulation alone) and represent the mean of three se3.5. Eﬀects of pharmacological inhibitors on TGF-b1-mediated
MMP-9 inhibition
We furthermore examined the abilities of various pharmaco-
logical inhibitors, i.e., tyrphostin 25 which is a highly speciﬁc
protein tyrosine kinase (PTK) inhibitor, SB203580 a speciﬁc
inhibitor for p38 MAPK, indomethacin an inhibitor of the
cyclooxygenase pathway, H-89 an inhibitor of cAMP-depen-
dent protein kinase, wortmannin that acts as a selective and
irreversible inhibitor of PI3-kinase and the highly speciﬁc
PKC inhibitor bisindolylmaleimide, to reverse the inhibitory
eﬀect of TGF-b1 on MMP-9 release. As shown in Fig. 5, H-
89, indomethacin, bisindolylmaleimide and wortmannin were
without eﬀect on TGF-b1-mediated MMP-9 inhibition.
SB205380 instead slightly reenforced the inhibitory eﬀect of
TGF-b1 (Fig. 5). In contrast, tyrphostin 25 markedly pre-
vented the inhibition of MMP-9 production by TGF-b1
(Fig. 5) thus suggesting PTK involvement in the pathway lead-
ing to MMP-9 inhibition by TGF-b1. The inability of PP2 to
prevent the inhibitory action of TGF-b1 excluded the partici-
pation of a PTK belonging to the Src family.
3.6. IFNs and TGF-b1 inhibit migration of monocytes through
matrigel in a MMP-9 dependent manner
Assuming that the production of MMPs may facilitate cell
migration across basal lamina, we investigated whether
MMP-9 secretion correlates with the transmigration of mono-
cytes across a reconstituted basement membrane using Trans-
wells where the upper chamber was coated with Matrigel.
Monocytes showed a signiﬁcant percentage of 18 h-migration
in the Matrigel-based assay (Fig. 6A). Neutralizing anti-
MMP-9 antibody and the synthetic MMP-9 inhibitor (2R)-
[4-biphenyl sulfonylamino]-N-hydroxy-3-phenyl propionamide
signiﬁcantly reduced the percentage of migration, respectively,
to 39% and 50% of the control (Fig. 6A). We further examined
the impact of IFN-a/b/-c or TGF-b1 on the transmigration of
monocytes. The percentage of migration of monocytes was sig-
niﬁcantly lower when the cells were incubated with IFN-b/-c orocytes treated with IFNs, TGF-b1 and AG490. Monocytes (1 · 106) were
L) for 24 h. Cells were pretreated with AG490 (5 lM) for 30 min before
escribed in Section 2. Whole cell lysates were separated by 12% SDS–
as assayed by ELISA. Data are calculated as percent of control (no
parate experiments ± S.D.
Fig. 5. Eﬀects of kinase inhibitors on TGF-b1-mediated inhibition of
MMP-9 production. Monocytes (1 · 106) were cultured in the absence
or presence of indomethacin (1 lM), H-89 (10 lM), bisindolylmale-
imide (10 lM), wortmannin (1 lM), SB203580 (5 lM), tyrphostin 25
(5 lM), or PP2 (10 lM) and/or TGF-b1 (10 ng/mL) for 24 h. MMP-9
production in in conditioned media of day-1 monocytes was assayed
by ELISA. Data are calculated as percent of control (no stimulation or
pharmacological inhibitor stimulation alone) and represent the mean
of n separate experiments. (n = 3, wortmannin; n = 4, indomethacin,
H-89, bisindolylmaleimide, SB203580, PP2; n = 7, tyrphostin 25).
Values are expressed as means ± S.D. \P < 0.010 compared with
control.
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lack of a signiﬁcant inhibitory eﬀect of IFN-a was related to
the low rate of IFN-a-mediated MMP-9 secretion seen before
24 h (data not shown). Visualization of migrated cells indi-
cated cell integrity for control and treated cells (Fig. 6B). This
was further conﬁrmed by the assessment that any treatment
did not lead to cell necrosis (data not shown, <15% dead cells).Fig. 6. Impact of MMP-9 antibody and inhibitor, IFNs and TGF-b1 on migr
plated (1 · 105 cells per chamber) in the Transwells coated with Matrigel as d
the absence or presence neutralizing MMP-9 antibody (10 lg/mL), MMP-9
onamide) (20 lg/mL), IFNs (1000 U/mL) or TGF-b1 (10 ng/mL). The control
migration (control) represented migration of untreated monocytes (15%). D
expressed as means ± S.D. \P < 0.005 for anti-MMP-9, IFN-a, FN-b and
\\\P < 0.008 for IFN-c compared with control. (B) Light microscopy of mono
(c) +MMP-9 inhibitor, (d) +IFN-a, (e) +IFN-b, (f) +IFN-c and (g) +TGF-4. Discussion
In the present study, we determined the inhibitory actions of
IFNs and TGF-b1 on MMP-9 expression and MMP-9-medi-
ated invasiveness of human monocytes.
TNF-a stimulates MMP-9 production in human monocytes
via NF-jB activation [14,19]. In this study, we showed that
monocytes upon culture rapidly released MMP-9 via endoge-
nous TNF-a, and such ability was maintained when cells dif-
ferentiated into macrophages. IFN-c and TGF-b1 which
both accelerated spontaneous diﬀerentiation of monocytes,
downregulated MMP-9 synthesis and release in diﬀerentiating
monocytes. IFN-a/-b, which did not aﬀect monocyte matura-
tion, transcriptionally repressed MMP-9 as eﬃciently as
IFN-c. This inhibition was speciﬁc for MMP-9 since IFNs
and TGF-b1 did not alter the production of MMP-2 under
the same experimental conditions. Our data therefore suggest
that MMP-9 production is not associated with the maturation
process of monocytes.
We previously showed in a model of epithelial tumor, that
IFN-mediated inhibition of MMP-9 expression occurred
through STAT1 activation leading to the expression of IRF-
1 which in turn inhibited NF-jB binding to the MMP-9 pro-
moter [30]. Here, IFN-mediated MMP-9 downregulation in
monocytes involved the IRF-1 pathway, since the JAK inhib-
itor AG490 blocked STAT1 and IRF-1 activation, and reverse
the inhibitory action of IFN on MMP-9 release.
A recent study showed that the suppression of MMP-9
transcription by TGF-b1 was mediated by a region of MMP-
9 promoter (670/591 bp) containing the NF-jB site (600/
590 bp) [36] and the IFN enhancer core sequence (5 0-
GGAATTCC-3 0, 600/593 bp) previously shown by us to
participate in the negative regulation of MMP-9 gene transcrip-
tion [30]. However, our data clearly indicated that TGF-b1 did
not aﬀect the STAT1/IRF-1 pathway. TGF-b1 suppressed
TNF-a-induced MMP-9 production by the myeloid Mono-
Mac6 cell line via a PGE2- and PKA-dependent mechanismation of monocytes through Matrigel. (A) Freshly isolated monocytes
escribed in Section 2, were submitted to migration for 18 h at 37 C in
inhibitor ((2R)-[4-biphenylsulfonylamino]-N-hydroxy-3-phenylpropi-
isotype (mIgG1) did not aﬀect monocyte transmigration. 100% relative
ata represent the mean of three independent experiments. Values are
TGF-b1; \\P < 0.020 for MMP-9 inhibitor compared with control;
cytes that migrated in the lower chamber. (a) minus, (b) +anti-MMP9,
b1. Magniﬁcation, 160·. Bar, 10 lm.
5492 J. Nguyen et al. / FEBS Letters 579 (2005) 5487–5493[37]. Here, the use of various inhibitors clearly excluded the
cyclooxygenase and PKA pathways, as well as the PI-3K and
PKC pathways. In contrast, a PTK activity appeared involved
in TGF-b1-mediated MMP-9 inhibition because treatment
with tyrphostin 25 resulted in a marked blockade of the inhib-
itory activity of TGF-b1. The picture emerges that TGF-b1
inhibits TNF-a-mediated MMP-9 induction in monocytes at
least in a PTK-dependent manner. The elucidation of the
PTK(s) involved requires further investigation.
We showed that blood monocytes migrate through reconsti-
tuted basement membrane (Matrigel) through a MMP-9-med-
iated transmigration process since MMP-9 antibody and
MMP-9 inhibitor signiﬁcantly reduced the migratory ability
of monocytes. Importantly, IFN- and TGF-b1-mediated
downregulation of MMP-9 elicited inhibition of monocyte
invasion across the Matrigel. These data demonstrate the crit-
ical roles of IFNs and TGF-b1 in the MMP-9-mediated inva-
sion of monocytes.
Collectively, our observations, by providing insights into the
mechanisms of MMP-9 inhibition by IFNs and TGF-b1, may
be useful as a strategy to attenuate MMP-9-mediated invasion
of monocytes and, possibly, of MMP-9-producing tumoral
cells in inﬂamed tissues.
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